Erratum: Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk (Pediatric Research (2013) 74 (721-729) DOI:10.1038/pr.2013.162);Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk

Pediatric Research

Volumn 74, Issue 6, 2013, Pages 721-729

  Phelps, Dale L ^a   Ward, Robert M ^b   Williams, Rick L ^c   Watterberg, Kristi L ^d   Laptook, Abbot R ^e   Wrage, Lisa A ^c   Nolen, Tracy L ^c   Fennell, Timothy R ^c   Ehrenkranz, Richard A ^f   Poindexter, Brenda B ^g   Michael Cotten, C ^h   Hallman, Mikko K ^i,j   Frantz III, Ivan D ^k   Faix, Roger G ^b   Zaterka Baxter, Kristin M ^c   Das, Abhik ^c   Bethany Ball, M ^l   Michael O'Shea, T ^m   Lacy, Conra Backstrom ^d   Walsh, Michele C ⁿ   Shankaran, Seetha ^o   Sánchez, Pablo J ^p   Bell, Edward F ^q   Higgins, Rosemary D ^r   more..

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c RTI INTERNATIONAL   (United States)

^d UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^e BROWN UNIVERSITY   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ UNIVERSITY OF OULU   (Finland)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k TUFTS MEDICAL CENTER   (United States)

^l STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m WAKE FOREST SCHOOL OF MEDICINE   (United States)

ⁿ CASE WESTERN RESERVE UNIVERSITY   (United States)

^o WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF TEXAS AT DALLAS   (United States)

^q UNIVERSITY OF IOWA   (United States)

^r EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INOSITOL; PLACEBO;

ABSENCE OF SIDE EFFECTS; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INFANT; LUNG DYSPLASIA; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETROLENTAL FIBROPLASIA; SINGLE DRUG DOSE; TREATMENT OUTCOME;

FEMALE; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INFUSIONS, INTRAVENOUS; INOSITOL; MALE; PLACEBOS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 84890692529     PISSN: 00313998     EISSN: 15300447     Source Type: Journal    
DOI: 10.1038/pr.2014.44     Document Type: Erratum

References (27)

1. Michell RH. Inositol derivatives: evolution and functions. Nat Rev Mol Cell Biol 2008;9:151-61.
2. Sauer K, Cooke MP. Regulation of immune cell development through soluble inositol-1,3,4,5-tetrakisphosphate. Nat Rev Immunol 2010;10:257-71.
3. Okazaki IJ, Moss J. Characterization of glycosylphosphatidylinositiolanchored, secreted, and intracellular vertebrate mono-ADP-ribosyltransferases. Annu Rev Nutr 1999;19:485-509.
4. Holub BJ. Metabolism and function of myo-inositol and inositol phospholipids. Annu Rev Nutr 1986;6:563-97.
5. Carver JD, Stromquist CI, Benford VJ, Minervini G, Benford SA, Barness LA. Postnatal inositol levels in preterm infants. J Perinatol 1997;17:389-92.
6. Bromberger P, Hallman M. Myoinositol in small preterm infants: relationship between intake and serum concentration. J Pediatr Gastroenterol Nutr 1986;5:455-8.
7. Brusati V, Jóźwik M, Jóźwik M, et al. Fetal and maternal non-glucose carbohydrates and polyols concentrations in normal human pregnancies at term. Pediatr Res 2005;58:700-4.
8. Hallman M, Järvenpää AL, Pohjavuori M. Respiratory distress syndrome and inositol supplementation in preterm infants. Arch Dis Child 1986;61:1076-83.
9. Hallman M, Arjomaa P, Hoppu K. Inositol supplementation in respiratory distress syndrome: relationship between serum concentration, renal excretion, and lung effluent phospholipids. J Pediatr 1987;110:604-10.
10. Hallman M, Pohjavuori M, Bry K. Inositol supplementation in respiratory distress syndrome. Lung 1990;168:Suppl:877-82.
11. Hallman M, Bry K, Hoppu K, Lappi M, Pohjavuori M. Inositol supplementation in premature infants with respiratory distress syndrome. N Engl J Med 1992;326:1233-9.
12. Friedman CA, McVey J, Borne MJ, et al. Relationship between serum inositol concentration and development of retinopathy of prematurity: a prospective study. J Pediatr Ophthalmol Strabismus 2000;37:79-86.
13. Howlett A, Ohlsson A, Plakkal N. Inositol for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev 2012;3:CD000366.
14. Stoll BJ, Hansen NI, Bell EF, et al.; Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010;126:443-56.
15. Meibohm B, Läer S, Panetta JC, Barrett JS. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005;7:E475-87.
16. Brown LD, Cheung A, Harwood JE, Battaglia FC. Inositol and mannose utilization rates in term and late-preterm infants exceed nutritional intakes. J Nutr 2009;139:1648-52.
17. Caspary WF, Crane RK. Active transport of myo-inositol and its relation to the sugar transport system in hamster small intestine. Biochim Biophys Acta 1970;203:308-16.
18. Nahapetian A, Young VR. Metabolism of 14C-phytate in rats: effect of low and high dietary calcium intakes. J Nutr 1980;110:1458-72.
19. Troyer DA, Schwertz DW, Kreisberg JI, Venkatachalam MA. Inositol phospholipid metabolism in the kidney. Annu Rev Physiol 1986;48:51-71.
20. Lewin LM, Melmed S, Passwell JH, et al. Myoinositol in human neonates: serum concentrations and renal handling. Pediatr Res 1978;12:3-6.
21. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr 1978;92:529-34.
22. Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria. Pediatr Clin North Am 1986;33:179-201.
23. Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005;32:441-57.
24. Mahmood I, Duan J. Population pharmacokinetics with a very small sample size. Drug Metabol Drug Interact 2009;24:259-74.
25. Bertrand J, Comets E, Mentré F. Comparison of model-based tests and selection strategies to detect genetic polymorphisms influencing pharmacokinetic parameters. J Biopharm Stat 2008;18:1084-102.
26. Holub BJ. The nutritional importance of inositol and the phosphoinositides. N Engl J Med 1992;326:1285-7.
27. Hayashi N, Kinoshita H, Yukawa E, Higuchi S. Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production. Br J Clin Pharmacol 1998;46:11-9.